Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• Personalis, Inc. (NASDAQ:PSNL) has received a consensus rating of "Buy" from five research firms, with an average price target of $7.42 for the stock.
• Institutional investors own 61.91% of Personalis, with significant increases in holdings by firms such as Lightspeed Management and Aberdeen Group.
• The company's latest earnings report showed a revenue of $17.20 million, which is below the estimated $20.12 million, and it reported an EPS of ($0.23), beating estimates.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has been assigned an average rating of "Buy" from the five research firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.4167.

A number of equities research analysts have weighed in on PSNL shares. Guggenheim started coverage on Personalis in a research note on Thursday, May 15th. They set a "buy" rating and a $6.00 price objective for the company. BTIG Research set a $6.00 price objective on Personalis in a research report on Wednesday, August 6th. HC Wainwright reduced their price objective on Personalis from $9.00 to $8.50 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Finally, Wall Street Zen lowered Personalis from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th.

Institutional Trading of Personalis

Several institutional investors have recently modified their holdings of PSNL. Lightspeed Management Company L.L.C. acquired a new stake in shares of Personalis in the fourth quarter valued at $47,169,000. Aberdeen Group plc lifted its stake in Personalis by 472.3% in the 1st quarter. Aberdeen Group plc now owns 1,704,784 shares of the company's stock worth $5,984,000 after acquiring an additional 1,406,895 shares in the last quarter. Geode Capital Management LLC lifted its stake in Personalis by 165.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company's stock worth $8,960,000 after acquiring an additional 851,422 shares in the last quarter. Blue Water Life Science Advisors LP lifted its stake in Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company's stock worth $10,997,000 after acquiring an additional 500,900 shares in the last quarter. Finally, ARK Investment Management LLC lifted its stake in Personalis by 6.1% in the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock worth $25,231,000 after acquiring an additional 412,762 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Stock Performance

PSNL stock opened at $4.83 on Friday. Personalis has a 1 year low of $2.83 and a 1 year high of $7.79. The firm has a market cap of $428.32 million, a P/E ratio of -3.77 and a beta of 1.86. The stock has a 50-day simple moving average of $5.94 and a 200-day simple moving average of $4.86.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts predict that Personalis will post -1.4 EPS for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.